IZQVF - Indivior PLC

Other OTC - Other OTC Delayed Price. Currency in USD
0.5280
-0.0270 (-4.86%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close0.5550
Open0.5158
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4950 - 0.5580
52 Week Range0.3500 - 1.5100
Volume17,204
Avg. Volume22,161
Market Cap356.885M
Beta (5Y Monthly)-0.61
PE Ratio (TTM)2.93
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 15, 2016
1y Target EstN/A
  • Reuters

    Indivior posts steep quarterly loss as copycat drugs bite, shares plunge

    The company's Suboxone has been among the main treatments for addiction through a growing epidemic of opioid abuse in the United States. A film variant of Suboxone has lost more than half its market share to cheaper rivals in the last year. Indivior's shares have also plunged, by nearly two-thirds in 2019, as it also battles a potentially crushing $3 billion fine for illegally marketing Suboxone.

  • Financial Times

    Indivior shares plunge as it warns of loss this year

    UK drugmaker Indivior has warned it could fall to a loss this year as its expects litigation related to its Suboxone opioid addiction treatment to have a “material impact” on earnings. The group reported a net loss of $55m for the three months to December 31, compared with a profit of $24m in the same period a year earlier. Shaun Thaxter, chief executive, said in a statement that “2019 was a challenging year for Indivior”, adding that 2020 “is shaping up to be a pivotal year”.

  • Are Insiders Buying Indivior PLC (LON:INDV) Stock?
    Simply Wall St.

    Are Insiders Buying Indivior PLC (LON:INDV) Stock?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • Did You Manage To Avoid Indivior's (LON:INDV) Devastating 87% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Indivior's (LON:INDV) Devastating 87% Share Price Drop?

    It's not possible to invest over long periods without making some bad investments. But you have a problem if you face...

  • PR Newswire

    New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes

    Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release injections showed that study participants who were treated with SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII), demonstrated improved or maintained patient-centered outcomes across the following measures:

  • Reuters

    UPDATE 2-New York, states reach $700 mln settlement with Reckitt over opioid probes

    New York and other states have reached a $700 million settlement deal with Reckitt Benckiser over allegations that the drug distributor improperly marketed a drug to treat opioid addiction, New York Attorney General Letitia James said on Wednesday. The deal is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. state and federal claims that Reckitt Benckiser's former pharmaceuticals business Indivior, before it was spun out, carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.

  • Is Indivior PLC (LON:INDV) Overpaying Its CEO?
    Simply Wall St.

    Is Indivior PLC (LON:INDV) Overpaying Its CEO?

    In 2014 Shaun Thaxter was appointed CEO of Indivior PLC (LON:INDV). This report will, first, examine the CEO...

  • Reuters

    UPDATE 1-Indivior profit rises on slower-than-expected Suboxone market share loss

    Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace than the company's previous modelling had expected. The maker of drugs that treat opioid addiction posted a pretax profit of $89 million in the second quarter ended June 30 from $78 million a year earlier. Revenue fell nearly 20% to $215 million in the quarter due to the expected decline in market share for Suboxone, but Indivior reaffirmed that it expects 2019 revenue to be between $670 million and $720 million.

  • Reuters

    Indivior loses appeal to block generic Suboxone opioid treatments

    The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.

  • Reuters

    UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments

    A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.

  • Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes
    Reuters

    Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

    The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.

  • Reuters

    UPDATE 2-Reckitt to pay $1.4 bln to end Indivior probe

    Britain's Reckitt Benckiser will pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior. Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) to resolve the investigation into a business that was wholly demerged from the company in 2014. The U.S. Justice Department had accused Indivior of illegally boosting prescriptions for the opioid addiction treatment, called Suboxone Film.

  • Zacks Small Cap Research

    DRRX: Highly Compelling Initial Ph2a DUR-928 Alcoholic Hepatitis Data. Final Data Later This Year Could Be Value Inflection Event

    Last week Durect Corp (DRRX) reported financial results for their first quarter ending March 31st and provided a pipeline development update. The development update was extensive and included highly compelling results of the first 10 patients enrolled in the DUR-928 Phase 2a alcoholic hepatitis trial. Relative to the financials, total revenue of $4.1M included $2.6M in product sales, mostly related to ALZET mini pumps and LACTEL biodegradable polymer products, as well as $1.5M in collaborative revenue.

  • Reuters

    Indivior signs deal to sell schizophrenia drug in Canada

    Perseris, launched in the United States in February, is approved by the FDA for the treatment of schizophrenia in adults. The drug delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended. Indivior, which gets most of its revenue from Suboxone in the United States, was indicted last month for illegal marketing of Suboxone in the U.S. and was fined $3 billion.

  • Reuters

    Indivior's Suboxone decline slower than feared as company bets on new opioid drug

    The U.S. Supreme Court earlier this year cleared the way for market access to cheaper alternatives to Indivior's blockbuster opioid addiction treatment Suboxone film, a move which the company itself said could result in the rapid loss of market share. The British based company, which reported revenue of over $1 billion (£766 million) last year - generated largely from the U.S. - said on Thursday it expects 2019 net revenue to fall to between $525 million and $575 million this year. Sales in the U.S., rose despite generic competition.